Remarkable progress in understanding molecular, cellular and structural viral biology over the last ten years has paved the way for a prosperous age of antivirals. The U.S. FDA has approved 27 new direct-acting antivirals (DAAs), marking a clear step forward compared to the previous 50 years (from 1962, when the first DAA was introduced into therapy, to 2012). Antiviral agents have been shown to play a crucial role in modern medicine, fighting infections, reducing disease severity and preventing viral spread. Their importance has been underscored during numerous global health crises affecting humans over the centuries. In this review, we provide a comprehensive analysis of the 27 newer FDA-approved DAAs, from discovery to final approval. We focus particularly on medicinal chemistry, covering design, optimization, mechanisms of action and co-crystallographic/Cryo-EM structures. In the final section, we provide a detailed discussion of the achievements made during the period under review. Additionally, given that the current antiviral arsenal is characterized by numerous limitations and is solely effective against a small number of viruses, leaving many others without effective treatment, an overview of innovative approaches and targets that could potentially address unmet clinical needs was also provided.
The identification of new targets to address unmet medical needs, better in a personalized way, is an urgent necessity. The introduction of PARP1 inhibitors into therapy, almost ten years ago, has represented a step forward this need being an innovate cancer treatment through a precision medicine approach. The PARP family consists of 17 members of which PARP1 that works by poly-ADP ribosylating the substrate is the sole enzyme so far exploited as therapeutic target. Most of the other members are mono-ADP-ribosylating (mono-ARTs) enzymes, and recent studies have deciphered their pathophysiological roles which appear to be very extensive with various potential therapeutic applications. In parallel, a handful of mono-ARTs inhibitors emerged that have been collected in a perspective on 2022. After that, additional very interesting compounds were identified highlighting the hot-topic nature of this research field and prompting an update. From the present review, where we have reported only mono-ARTs inhibitors endowed with the appropriate profile of pharmacological tools or drug candidate, four privileged scaffolds clearly stood out that constitute the basis for further drug discovery campaigns.
Here we report [1,2,4]triazolo[3,4- b ]benzothiazole (TBT) as a new inhibitor scaffold, which competes with nicotinamide in the binding pocket of human poly- and mono-ADP-ribosylating enzymes. The binding mode was studied through analogs and their crystal structures with TNKS2, PARP2, PARP14 and PARP15. Based on the substitution pattern, we were able to identify The 3-amino derivatives 21 (OUL243) and 27 (OUL232), as inhibitors of mono-ARTs PARP7, PARP10, PARP11, PARP12, PARP14 and PARP15 at nM potencies, with compound 27 being the most potent PARP10 inhibitor described to date with an IC 50 of 7.8 nM and the first PARP12 inhibitor ever reported. On the contrary, hydroxy derivative 16 (OUL245) inhibits poly-ARTs with a selectivity towards PARP2. The scaffold does not possess inherent cell toxicity and the inhibitors can enter cells and engage with the target protein. This, together with favorable ADME properties, demonstrates the potential of the TBT scaffold for future drug development efforts towards selective inhibitors against specific enzymes.